Pre-Clinical News
-
Showcase
Kadimastem Awarded Patent in Japan for AstroRx® For ALS and Drug Screening
Kadimastem Ltd. (TASE: KDST), a clinical stage cell therapy company developing a treatment for ALS, exploring one for multiple sclerosis and developing a potential cure for diabetes, has received a patent from the Japan Patent Office for AstroRx® for the treatment of ALS and drug screening. The patent also protects AstroRx® for the treatment of multiple sclerosis. AstroRx® is ...
-
Showcase
Alfa Chemistry Provides Fluorophores for the Synthesis of Small-Molecule Fluorescent Probes
As the popularity of small-molecule fluorescent probes enhances, the demand for fluorophores also rises. In a recent statement, Alfa Chemistry announced the release of varieties of fluorophores, which are mainly used for synthesizing small-molecule fluorescent probes and as a tool widely utilized in bioanalysis, environmental monitoring, food detection, and clinical disease diagnosis. Fluorescent ...
-
Showcase
Koning Ends the Year with $2.6M Republic Raise
NORCROSS, Ga., Feb. 1, 2022 /PRNewswire/ -- Koning, a growing medical device startup company based outside Atlanta, had a successful conclusion to 2021. The company recently finished their first Republic crowdfunding campaign, exceeding capital targets, and raising over $2.6M in only 5 months. Koning's FDA breast screening trial is also underway with participating clinics in Daytona Beach, FL and ...
-
Showcase
Neeuro (Singapore) and epihunter (Belgium) partner to create new and innovative digital solutions for people with brain disorders
On March 15th 2015, Tim Buckinx’ son said: “Papa, you work in digital, can’t you create a light that turns on when my brain switches off?” At ten years old, he was simply fed up with the daily impact of his refractory epilepsy. That pain became a vision, and that vision became the Belgian digital therapeutics company epihunter, aimed at enabling people with a brain ...
By Epihunter NV
-
Showcase
Koning Begins FDA Clinical Screening Trial in Daytona Beach, Florida
DAYTONA BEACH, Fla., Nov. 1, 2021 /PRNewswire/ -- Koning begins an FDA screening trial this month for their no-compression, Isotropic, 3-dimensional breast imaging device. The company received FDA PMA approval for commercial, diagnostic use in 2017. Since then, the Koning Breast CT (KBCT) has been installed in clinics and universities in the US and globally. "This FDA screening trial is a major ...
-
Showcase
Corify Care Participates In the Atrial Signals Workshop 2021
Last week (23-25th September) took place the workshop Atrial Signals 2021 http://www.atrial-signals.kit.edu/ at the Karlsruhe Institute of Technology (KIT), thanks to the joint collaboration of the Institute of Biomedical Engineering (IBT) and the Städtisches Klinikum Karlsruhe. Andreu Climent, CEO of Corify Care presented Acorys, our Non-invasive Electrocardiographic Imaging device of the ...
-
Showcase
Atmo Biosciences awarded Australian Government grant to automate and scale-up manufacturing of ingestible gas-sensing capsule
Atmo Biosciences has been awarded an Australian Government Manufacturing Modernisation Fund (MMF) grant to support manufacturing automation and scale-up for the Atmo Gas-Sensing Capsule. The Round 2 MMF grants, part of the Government’s Modern Manufacturing Strategy, are for small-medium sized businesses to transform manufacturing and to support job growth and develop a more skilled ...
-
Showcase
Neurescue`s Breakthrough Intelligent Balloon Catheter FDA 510(k) Cleared for Hemorrhage Control and IDE Approved for Cardiac Arrest
COPENHAGEN, Denmark--(BUSINESS WIRE)--Neurescue, a medical device company developing innovative cardiovascular solutions to improve the outcomes for emergency patients, today announced that the U.S. Food and Drug Administration (FDA) has granted 510(k) clearance to market the company’s NEURESCUE® device for temporary occlusion of large vessels, including patients requiring emergency ...
By Neurescue
-
Showcase
FemTech Company MobileODT awarded prestigious National Cancer Institute (NCI) SBIR grant of $2.3 million
MobileODT, a FemTech company producing the latest digital innovation in cervical screening, has been awarded a prestigious Small Business Innovation Research Authority grant of $2.3 million. This grant is presented by the United States National Cancer Institute (NCI) to leading companies that are technologically and clinically advanced to support the NCI’s goal of reducing suffering and ...
By MobileODT
-
Showcase
Empatica partnering with U.S. Army MRDC to deploy COVID-19 early detection wearable
BOSTON, Nov. 6, 2020 /PRNewswire/ -- Empatica has been selected by the U.S. Army Medical Research and Development Command (USAMRDC) to deploy a wearable and algorithm that enable the early and pre-symptomatic detection of COVID-19. The project's focus is on protecting the health of the general population by preventing outbreaks via early detection and alerting. Empatica's Aura algorithm gives a ...
-
Showcase
Empatica and BARDA Join Forces to Validate Wearable System That Detects COVID-19 Before Symptoms Appear
BOSTON, June 19, 2020 /PRNewswire/ -- Digital healthcare company Empatica announces a pioneering new partnership with the Biomedical Advanced Research and Development Authority ("BARDA"), part of the Office of the Assistant Secretary for Preparedness and Response at the U.S. Department of Health and Human Services (HHS), to validate an early warning system for COVID-19 and other respiratory ...
-
Showcase
Empatica Announces EmbracePlus: NASA Medical Quality in a Down-to-Earth Smart Watch
BOSTON, Nov. 19, 2019 /PRNewswire/ -- On November 19th, 2019, Empatica is announcing EmbracePlus, their new smart watch built in partnership with TRISH, the Translational Research Institute for Space Health. NASA's Human Research Program partners with external entities to develop new approaches that can help reduce the risk to humans on long exploration missions. One such entity is TRISH, who ...
-
Showcase
New device offers a mouthful of data for chronic diseases
Aidar Health, formerly known as Multisensor Diagnostics, has developed a portable hand-held device that allows patients to measure and track vital signs in a matter of seconds. Roughly the size of an iPhone, MouthLab consists of a hand unit and a mouthpiece that fits between the teeth and lips. The mouthpiece uses special sensors to gather information from breathing patterns, saliva and blood ...
By Aidar Health
-
Chrysalis BioTherapeutics Receives Additional Funding from the National Institutes of Health for COVID-19 Therapeutic Development
Chrysalis BioTherapeutics, Inc., a clinical-stage biotechnology company developing regenerative drugs that target vascular endothelial and progenitor cells, announced today that the National Institute of Allergy and Infectious Diseases (NIAID), part of the National Institutes of Health (NIH), has provided additional funding in the amount of $587,995 to its contract with Chrysalis, bringing the ...
-
Drug developed by Galveston scientist to be tested for COVID-19 use
A drug developed by an independent biotech firm headquartered in Galveston will be tested for clinical application to problems related to COVID-19, thanks to a $1.5 million grant from the federal government to be released June 1. Chrysalin, or TP508, a regenerative thrombin peptide developed by scientist Darrell Carney, has been tested in human clinical trials for skin and bone tissue repair ...
-
Chrysalis BioTherapeutics Receives Funding from the National Institutes of Health for COVID-19 Therapeutic Development
Chrysalis BioTherapeutics, Inc., a clinical-stage biotechnology company developing regenerative drugs for acute organ injury caused by radiation exposure, announced today that the National Institute of Allergy and Infectious Disease (NIAID), part of the National Institutes of Health, awarded Chrysalis $912,157 to fund preclinical development of its investigational drug TP508 for SARS-CoV-2 ...
-
New Startup Makes Developing Gene Therapies Faster and Easier
Today, cell and gene therapies treat and could even cure terminal diseases like leukemia and spinal muscular atrophy, but unlocking their full potential is still a challenge for therapy developers. Both types of therapies rely on living cells comprised of hundreds of thousands of biomolecules to work in unison. And in order for therapy developers to meet safety and production ...
-
Kadimastem Granted a Patent in Israel for the Treatment of ALS
NESS ZIONA, ISRAEL, March 9, 2021 – Kadimastem Ltd. (TASE: KDST), a clinical stage cell therapy company, announced that it has been granted a patent by The Israel Patent Office for its differentiated human astrocytes from human pluripotent stem cells for use in the treatment and drug screening of Amyotrophic Lateral Sclerosis (ALS). Specifically, the patent allows for the innovative ...
-
Morgridge Postdoc Awarded First AAAS Science & Technology Policy Fellowship in the U.S. Department of the Treasury Das will be the first ever AAAS Fellow accepted into a position at the Department of the Treasury
Ask anyone participating in a cultural exchange: It’s helpful to know the local language. Morgridge Postdoctoral Fellow Amritava Das knows this well, and not just because he speaks five languages. His career has been defined by bridging the different languages of science and ethics, and he will soon be taking that expertise to the U.S. Department of the Treasury via a ...
-
Seres Therapeutics Presents Microbiome Therapeutic Research at the 2022 American Society of Clinical Oncology (ASCO) Annual Meeting
CAMBRIDGE, Mass.--(BUSINESS WIRE)--Jun. 1, 2022-- Seres Therapeutics, Inc. (Nasdaq: MCRB), a leading microbiome therapeutics company, announced the presentation of preclinical data supporting further investigation of a rationally designed microbial consortium candidate (DE486) to prevent or treat gastrointestinal (GI) mucositis – a common and often painful complication of radiation and ...
Need help finding the right suppliers? Try XPRT Sourcing. Let the XPRTs do the work for you